Pisani E, Pavone-Macaluso M, Rocco F, Piaia F, Pirozzi F, Rotolo U, Lamartina M, Melloni D, Larcker P
Urol Res. 1982 Feb;10(1):41-4. doi: 10.1007/BF00256523.
A new combination of trimethoprim with a sulphonamide, named Kelfiprim, differs from cotrimoxazole in that: a) the sulpha drug is sulphamethopyrazine instead of sulphamethoxazole; b) the trimethoprim to sulpha ratio is 5:4 instead of 1:5; c) the presence of a long-acting sulphonamide allows the administration of a daily dose of one capsule, following an initial loading dose of two capsules; d) a reduced amount of trimethoprim is given, as compared to cotrimoxazole, without any decrease of efficacy. Kelfiprim [KP] was compared to cotrimoxazole [Co] in a multicentre double blind trial. Sixty four patients suffering from acute and chronic infections of the upper and lower urinary tract entered the study. Urine sterilisation and clinical improvement without relapses showed no differences from the two treatment groups. Tolerance was excellent except in two patients, one treated with KP and the other treated with Co, who showed a transient exanthema.
一种名为凯尔菲普明（Kelfiprim）的甲氧苄啶与磺胺类药物的新组合与复方新诺明的不同之处在于：a）磺胺类药物是磺胺甲基吡嗪而非磺胺甲恶唑；b）甲氧苄啶与磺胺的比例为5:4而非1:5；c）长效磺胺的存在使得在初始负荷剂量为两粒胶囊后，每日服用一粒胶囊即可；d）与复方新诺明相比，甲氧苄啶的用量减少，但疗效并未降低。在一项多中心双盲试验中，对凯尔菲普明[KP]与复方新诺明[Co]进行了比较。64名患有上、下尿路感染的急性和慢性感染患者进入该研究。两个治疗组在尿液杀菌和临床改善且无复发方面没有差异。除两名患者外，耐受性良好，一名接受KP治疗，另一名接受Co治疗，他们出现了短暂的皮疹。
